Cargando…

From targeted therapy to a novel way: Immunogenic cell death in lung cancer

Lung cancer (LC) is one of the most incident malignancies and a leading cause of cancer mortality worldwide. Common tumorigenic drivers of LC mainly include genetic alterations of EGFR, ALK, KRAS, BRAF, ROS1, and MET. Small inhibitory molecules and antibodies selectively targeting these alterations...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Jiawei, Xiong, Yiyi, Xu, Zhou, Xing, Hongquan, Zhou, Lingyun, Zhang, Xinyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816397/
https://www.ncbi.nlm.nih.gov/pubmed/36619616
http://dx.doi.org/10.3389/fmed.2022.1102550
_version_ 1784864521161015296
author Xu, Jiawei
Xiong, Yiyi
Xu, Zhou
Xing, Hongquan
Zhou, Lingyun
Zhang, Xinyi
author_facet Xu, Jiawei
Xiong, Yiyi
Xu, Zhou
Xing, Hongquan
Zhou, Lingyun
Zhang, Xinyi
author_sort Xu, Jiawei
collection PubMed
description Lung cancer (LC) is one of the most incident malignancies and a leading cause of cancer mortality worldwide. Common tumorigenic drivers of LC mainly include genetic alterations of EGFR, ALK, KRAS, BRAF, ROS1, and MET. Small inhibitory molecules and antibodies selectively targeting these alterations or/and their downstream signaling pathways have been approved for treatment of LC. Unfortunately, following initial positive responses to these targeted therapies, a large number of patients show dismal prognosis due to the occurrence of resistance mechanisms, such as novel mutations of these genes and activation of alternative signaling pathways. Over the past decade, it has become clear that there is no possible cure for LC unless potent antitumor immune responses are induced by therapeutic intervention. Immunogenic cell death (ICD) is a newly emerged concept, a form of regulated cell death that is sufficient to activate adaptive immune responses against tumor cells. It transforms dying cancer cells into a therapeutic vaccine and stimulates long-lasting protective antitumor immunity. In this review, we discuss the key targetable genetic aberrations and the underlying mechanism of ICD in LC. Various agents inducing ICD are summarized and the possibility of harnessing ICD in LC immunotherapy is further explored.
format Online
Article
Text
id pubmed-9816397
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98163972023-01-07 From targeted therapy to a novel way: Immunogenic cell death in lung cancer Xu, Jiawei Xiong, Yiyi Xu, Zhou Xing, Hongquan Zhou, Lingyun Zhang, Xinyi Front Med (Lausanne) Medicine Lung cancer (LC) is one of the most incident malignancies and a leading cause of cancer mortality worldwide. Common tumorigenic drivers of LC mainly include genetic alterations of EGFR, ALK, KRAS, BRAF, ROS1, and MET. Small inhibitory molecules and antibodies selectively targeting these alterations or/and their downstream signaling pathways have been approved for treatment of LC. Unfortunately, following initial positive responses to these targeted therapies, a large number of patients show dismal prognosis due to the occurrence of resistance mechanisms, such as novel mutations of these genes and activation of alternative signaling pathways. Over the past decade, it has become clear that there is no possible cure for LC unless potent antitumor immune responses are induced by therapeutic intervention. Immunogenic cell death (ICD) is a newly emerged concept, a form of regulated cell death that is sufficient to activate adaptive immune responses against tumor cells. It transforms dying cancer cells into a therapeutic vaccine and stimulates long-lasting protective antitumor immunity. In this review, we discuss the key targetable genetic aberrations and the underlying mechanism of ICD in LC. Various agents inducing ICD are summarized and the possibility of harnessing ICD in LC immunotherapy is further explored. Frontiers Media S.A. 2022-12-23 /pmc/articles/PMC9816397/ /pubmed/36619616 http://dx.doi.org/10.3389/fmed.2022.1102550 Text en Copyright © 2022 Xu, Xiong, Xu, Xing, Zhou and Zhang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Xu, Jiawei
Xiong, Yiyi
Xu, Zhou
Xing, Hongquan
Zhou, Lingyun
Zhang, Xinyi
From targeted therapy to a novel way: Immunogenic cell death in lung cancer
title From targeted therapy to a novel way: Immunogenic cell death in lung cancer
title_full From targeted therapy to a novel way: Immunogenic cell death in lung cancer
title_fullStr From targeted therapy to a novel way: Immunogenic cell death in lung cancer
title_full_unstemmed From targeted therapy to a novel way: Immunogenic cell death in lung cancer
title_short From targeted therapy to a novel way: Immunogenic cell death in lung cancer
title_sort from targeted therapy to a novel way: immunogenic cell death in lung cancer
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816397/
https://www.ncbi.nlm.nih.gov/pubmed/36619616
http://dx.doi.org/10.3389/fmed.2022.1102550
work_keys_str_mv AT xujiawei fromtargetedtherapytoanovelwayimmunogeniccelldeathinlungcancer
AT xiongyiyi fromtargetedtherapytoanovelwayimmunogeniccelldeathinlungcancer
AT xuzhou fromtargetedtherapytoanovelwayimmunogeniccelldeathinlungcancer
AT xinghongquan fromtargetedtherapytoanovelwayimmunogeniccelldeathinlungcancer
AT zhoulingyun fromtargetedtherapytoanovelwayimmunogeniccelldeathinlungcancer
AT zhangxinyi fromtargetedtherapytoanovelwayimmunogeniccelldeathinlungcancer